Collegium Pharmaceutical Inc Stock Price, News & Analysis

Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in three upcoming investor conferences in September 2025. The company will attend the 2025 Wells Fargo Healthcare Conference on September 4 in Boston, participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8 at 2:35 p.m. ET in New York, and present at the H.C. Wainwright Global Investment Conference on September 9 at 10:30 a.m. ET in New York.

Live webcasts of the fireside chats will be accessible through Collegium's investor relations website, with replays available for 90 days after the presentations.

Collegium Pharmaceutical (Nasdaq: COLL) will present nine posters featuring real-world data from its pain management portfolio at PAINWeek 2025 in Las Vegas from September 2-5, 2025. The presentations will focus on data from their key products BELBUCA® and XTAMPZA® ER.

The research includes studies on treatment characteristics, safety profiles, economic burden, and clinical outcomes for chronic low back pain patients. Chief Medical Officer Thomas Smith emphasized that these findings will provide healthcare professionals with valuable insights to support clinical decision-making. The poster session is scheduled for September 4, 2025, from 4:00 to 5:30 PM PT.

Collegium Pharmaceutical (Nasdaq: COLL) reported strong Q2 2025 financial results, achieving record quarterly revenue of $188.0 million, up 29% year-over-year. The company's ADHD medication Jornay PM generated record revenue of $32.6 million with 23% prescription growth, while the pain portfolio contributed $155.4 million, up 7% year-over-year.

The company raised its 2025 guidance, now expecting full-year revenue between $745-760 million and adjusted EBITDA of $440-455 million. Q2 highlights include adjusted EBITDA of $105.1 million and cash position of $222.2 million. The Board authorized a new $150 million share repurchase program through 2026, following completion of a $25 million accelerated share repurchase.

Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, before market opening. The company will host a conference call and webcast at 8:00 a.m. ET following the release.

Investors can access the conference call via (877) 407-8037 (U.S.) or (201) 689-8037 (International). An audio webcast will be available on the company's website investor section and will remain accessible for replay approximately two hours after the event.

Collegium Pharmaceutical (Nasdaq: COLL) has announced a new $150 million share repurchase program effective through December 31, 2026. This program replaces their previous $150 million authorization from January 2024, which expired with $65 million unused.

The company has demonstrated strong commitment to shareholder value, having returned $222 million to shareholders through repurchase programs since 2021. This includes a $25 million accelerated share repurchase initiated in May 2025. As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding.

Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in two upcoming investor conferences:

1. The Mizuho Neuro & Ophthalmology Summit 2025, where management will participate in a panel presentation on Wednesday, May 21, 2025, at 11:25 a.m. ET

2. The Jefferies Global Healthcare Conference, featuring a presentation on Thursday, June 5, 2025, at 1:25 p.m. ET. This presentation will be webcast live and accessible through the company's investor relations website, with a replay available for 90 days following the event.

Collegium Pharmaceutical (NASDAQ: COLL) has announced a $25 million Accelerated Share Repurchase (ASR) agreement with Jefferies LLC. This ASR is part of a larger $150 million share repurchase program authorized in January 2024, with $65 million remaining after this transaction. The company will receive an initial delivery of 692,281 shares at $28.89 per share, representing approximately 80% of expected total shares under the ASR.

The company reported strong Q1 2025 performance with 23% year-over-year revenue growth, driven by its pain portfolio and ADHD medicine Jornay PM®. The final settlement of the ASR is expected by Q3 2025, with the final share count based on volume-weighted average prices. As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding.

Collegium Pharmaceutical (NASDAQ: COLL) reported strong Q1 2025 financial results with total revenue of $177.8M, up 23% YoY. The company's ADHD medication Jornay PM saw 24% YoY prescription growth, generating $28.5M in revenue. The pain portfolio contributed $149.2M, up 3% YoY, with growth across all core products: Belbuca ($51.7M), Xtampza ER ($47.6M), and Nucynta ($47.1M). The company expanded its ADHD sales force by 55 representatives to approximately 180 total. Collegium ended Q1 with $197.8M in cash and equivalents, announced a $25M accelerated share repurchase program, and reaffirmed its 2025 guidance of $735-750M in product revenues. The company maintained strong cash generation, paying down $16.1M in debt while strengthening its leadership team and board composition.

Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results.

Investors can access the conference call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers. An audio webcast will be available through the Investors section of Collegium's website and will remain accessible for replay approximately two hours after the event.